In addition to those conducted for cancer, pre-clinical and clinical studies were performed to evaluate the efficacy of saracatinib in Alzheimer’s disease (AD) treatment, considering the association between Fyn and the cascade Aβ-PRPc [5,6]. The gene discussed is FYN; the disease is early-onset autosomal dominant Alzheimer disease.